HHT drug trial pulled before it even started
Disease control
Terminated
This was a planned early-stage study of a new drug called TER-1754 for people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes frequent nosebleeds and abnormal blood vessels. The trial aimed to test safety and find the right dose, but it was withdrawn bef…
Phase: PHASE1 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC